Over the past decade, we made strategic investments in two integrated BSL-2 systems to automate central assays used in vaccine discovery and early-stage development. Key factors contributing to our success involved standardizing mechanistically identical assays into operational workflows and making these systems more accessible to non-expert users. I will share insights about system design, the significance of standardization and assay redevelopment for achieving walk-away automation, the indispensable role of digitalization in complete automation, and notably, the anticipated performance enhancements from such projects.
Speaker: Krisztian Kaszas, Janssen